Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

Brinckerhoff CE.

J Cell Physiol. 2017 Oct;232(10):2674-2678. doi: 10.1002/jcp.25796. Epub 2017 Mar 6. Review.

2.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.

Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.

Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.

PMID:
26974965
3.

What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?

Brinckerhoff CE.

Melanoma Manag. 2016 Mar;3(1):5-8. doi: 10.2217/mmt.15.36. Epub 2016 Feb 18. No abstract available.

4.

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.

Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.

5.

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.

Jenkins MH, Brinckerhoff CE, Mullins DW.

PLoS One. 2015 Mar 23;10(3):e0121140. doi: 10.1371/journal.pone.0121140. eCollection 2015.

6.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

7.

BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.

Whipple CA, Brinckerhoff CE.

Br J Cancer. 2014 Oct 14;111(8):1625-33. doi: 10.1038/bjc.2014.452. Epub 2014 Aug 12.

8.

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6. No abstract available.

9.

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.

Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE.

J Cell Physiol. 2013 Apr;228(4):773-80. doi: 10.1002/jcp.24225.

10.

Distal interleukin-1β (IL-1β) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression.

Schmucker AC, Wright JB, Cole MD, Brinckerhoff CE.

J Biol Chem. 2012 Jan 6;287(2):1189-97. doi: 10.1074/jbc.M111.264077. Epub 2011 Nov 18.

11.

The 'RASor's' edge: Ras proteins and matrix destruction in arthritis.

Schmucker AC, Brinckerhoff CE.

Arthritis Res Ther. 2009;11(6):136. doi: 10.1186/ar2840. Epub 2009 Dec 11.

12.

Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.

Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE.

J Autoimmun. 2009 Nov-Dec;33(3-4):214-21. doi: 10.1016/j.jaut.2009.09.011. Epub 2009 Oct 1. Review.

13.

A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.

Blackburn JS, Liu I, Coon CI, Brinckerhoff CE.

Oncogene. 2009 Dec 3;28(48):4237-48. doi: 10.1038/onc.2009.272. Epub 2009 Sep 7.

14.

CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells.

Eck SM, Côté AL, Winkelman WD, Brinckerhoff CE.

Mol Cancer Res. 2009 Jul;7(7):1033-44. doi: 10.1158/1541-7786.MCR-09-0015. Epub 2009 Jul 7.

15.

Site controlled transgenic mice validating increased expression from human matrix metalloproteinase (MMP-1) promoter due to a naturally occurring SNP.

Coon CI, Fiering S, Gaudet J, Wyatt CA, Brinckerhoff CE.

Matrix Biol. 2009 Sep;28(7):425-31. doi: 10.1016/j.matbio.2009.06.003. Epub 2009 Jul 3.

16.

PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.

Petrella BL, Brinckerhoff CE.

Cancer Biol Ther. 2009 Jul;8(14):1389-401. Epub 2009 Jul 30.

17.

Wild-type versus mutant MMP-8 in melanoma: 'when you come to a fork in the road, take it'.

Blackburn JS, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2009 Jun;22(3):248-50. doi: 10.1111/j.1755-148X.2009.00573.x. Epub 2009 Apr 15. No abstract available.

PMID:
19397759
18.

Diesel exhaust particles activate the matrix-metalloproteinase-1 gene in human bronchial epithelia in a beta-arrestin-dependent manner via activation of RAS.

Li J, Ghio AJ, Cho SH, Brinckerhoff CE, Simon SA, Liedtke W.

Environ Health Perspect. 2009 Mar;117(3):400-9. doi: 10.1289/ehp.0800311. Epub 2008 Oct 29. Erratum in: Environ Health Perspect. 2009 Apr;117(4):A143.

19.

Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.

Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE.

Arthritis Res Ther. 2008;10(6):R139. doi: 10.1186/ar2564. Epub 2008 Dec 1.

20.

Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.

Blackburn JS, Brinckerhoff CE.

Am J Pathol. 2008 Dec;173(6):1736-46. doi: 10.2353/ajpath.2008.080512. Epub 2008 Nov 6.

21.

Identification of a cigarette smoke-responsive region in the distal MMP-1 promoter.

Mercer BA, Wallace AM, Brinckerhoff CE, D'Armiento JM.

Am J Respir Cell Mol Biol. 2009 Jan;40(1):4-12. doi: 10.1165/rcmb.2007-0310OC. Epub 2008 Jul 10.

22.

Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model.

Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE.

Breast Cancer Res Treat. 2009 Jul;116(1):79-90. doi: 10.1007/s10549-008-0085-3. Epub 2008 Jul 3.

23.
24.
25.

Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand.

Burrage PS, Huntington JT, Sporn MB, Brinckerhoff CE.

Arthritis Rheum. 2007 Mar;56(3):892-904.

26.

Molecular targets in osteoarthritis: metalloproteinases and their inhibitors.

Burrage PS, Brinckerhoff CE.

Curr Drug Targets. 2007 Feb;8(2):293-303. Review.

PMID:
17305507
27.

Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURR1 in cartilage.

Mix KS, Attur MG, Al-Mussawir H, Abramson SB, Brinckerhoff CE, Murphy EP.

J Biol Chem. 2007 Mar 30;282(13):9492-504. Epub 2007 Feb 5.

29.
30.

Matrix metalloproteinases: role in arthritis.

Burrage PS, Mix KS, Brinckerhoff CE.

Front Biosci. 2006 Jan 1;11:529-43. Review.

PMID:
16146751
32.

Selective retinoic acid receptor ligands for rheumatoid arthritis.

Beehler BC, Brinckerhoff CE, Ostrowski J.

Curr Opin Investig Drugs. 2004 Nov;5(11):1153-7. Review.

PMID:
15573865
33.

Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis.

Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ.

Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S129-37. Review.

PMID:
15480055
34.

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.

Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, Brinckerhoff CE.

J Biol Chem. 2004 Aug 6;279(32):33168-76. Epub 2004 Jun 7.

36.
37.

Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter.

Tower GB, Coon CI, Belguise K, Chalbos D, Brinckerhoff CE.

Eur J Biochem. 2003 Oct;270(20):4216-25.

38.

Retinoids and rexinoids for the 21st century: a brave new world for arthritis.

Brinckerhoff CE, Sporn MB.

J Rheumatol. 2003 Feb;30(2):211-3. Review. No abstract available.

PMID:
12563669
39.
40.
42.

Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells.

Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE.

Biochim Biophys Acta. 2002 Apr 24;1586(3):265-74.

43.

Matrix metalloproteinases: a tail of a frog that became a prince.

Brinckerhoff CE, Matrisian LM.

Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14. Review.

PMID:
11994741
44.

Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark?

Mengshol JA, Mix KS, Brinckerhoff CE.

Arthritis Rheum. 2002 Jan;46(1):13-20. Review. No abstract available.

45.

Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.

Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.

Oncogene. 2002 Jan 3;21(1):108-18.

46.

Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta.

Vincenti MP, Brinckerhoff CE.

Arthritis Res. 2001;3(6):381-8. Epub 2001 Sep 18.

49.
50.

The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK?

Vincenti MP, Brinckerhoff CE.

J Clin Invest. 2001 Jul;108(2):181-3. No abstract available.

Supplemental Content

Loading ...
Support Center